RH Nanopharmaceuticals was incorporated in 2017. The medication that is being reformulated into many delivery systems is called Salsalate. Quite remarkably this drug was first made in 1907 and was called Diplosal (meaning two molecules “Diplo” of salicylic acid “Sal”). It was manufactured by Boehringer Mannheim in Germany.to compete with acetylsalicylic acid known as Aspirin which was made by Bayer in 1897 by a chemist named Felix Hoffman. Even in that time, Aspirin was noted by doctors and patients to have serious gastrointestinal side effects including life threatening and deadly gastric bleeding. Diplosal was used in Europe for arthritis with great success. It then came to America in 1910 where it too was used for arthritis. It was noted by Dr. Levy in his seminal paper published in the Klinica Berliner in 1909 that Diplosal unlike Aspirin had none of the gastrointestinal side effects and was recommended as the drug of choice for arthritis sufferers (in those days arthritis was referred to as “rheumatism”, meaning a “condition of the joints”.)
RH Nanopharmaceuticals in not only seeking NDA approval of the 109 year old salsalate in the 500 mg and 750 mg twice daily formulation for arthritis and other inflammatory conditions, but has produced nanoparticles of salsalate.
RH Nanopharmaceuticals decided to produce a nanoparticle of salsalate in order to achieve a faster onset of action, longer duration of action and better anti-inflammatory effects in patients.
We are very proud of our exciting history and look forward to having many formulations of salsalate produced to help all inflammatory disorders. These reformulations of salsalate might very well revolutionize the field of anti-inflammatory treatments as it is among the safest if not the safest and most effective such treatment.